People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is ...

Some people may turn to private healthcare providers in order to get their hands on the weight loss jabs. However, Britons ...

The phase 3 STEP UP trial enrolled 1407 adults aged 18 years and older with a body mass index of at least 30kg/m2 and without diabetes.

Novo Nordisk's STEP UP trial shows semaglutide 7.2 mg delivers superior weight loss and safety compared to lower doses and ...

Novo Nordisk (NVO) announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is a ...

Ozempic and Wegovy have become popular options for people looking to lose weight, but there are some risks and side effects ...

GLP-1 drugs do a lot more than just help you lose weight. They can help your heart, brain, and more, but beware what they ...

Novo Nordisk said on Friday a late-stage trial with a high-dose version of its weight loss drug semaglutide helped overweight ...

A shake-up may be brewing in the market for GLP-1 diet drugs Friday, and it's making itself felt all across the field of ...

The race is on for new drugs that suppress appetite, improve glucose regulation and can replace injections. But do they ...

Some people are microdosing certain weight loss drugs in an attempt to reap some of the drugs' benefits with fewer of their side effects. But doctors specializing in weight loss say that ...